Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macupatide in Type 2 Diabetes
NCT05407961Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2022
- Primary completion
- Jan 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of macupatide in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Treatment Emergent Adverse Events at 16 weeks and Total Clamp Disposition Index (cDI) at 12 weeks. Started Jun 2022; status: completed.
02
Drugs
macupatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05407961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05407961.